Norbergenin prevents LPS-induced inflammatory responses in macrophages through inhibiting NFκB, MAPK and STAT3 activation, and blocking metabolic reprogramming

Inflammation is thought to be a key cause of many chronic diseases. However, current therapeutic agents to control inflammation have limited long-term use potential due to various side effects. This study aimed to determine the preventive effects of norbergenin on LPS-induced inflammation and elucidate the underlying mechanisms.